TRexBio reports positive Phase 1 results for TRB-061 and completes IPO
TRexBio reported positive proof-of-mechanism results for its Treg activator TRB-061, with Phase 1b data expected in mid-2027, backed by a completed $133.5 million IPO.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed